Sn-117m has been extensively investigated in multiple animal and human trials, and has safely and successfully treated a number of inflammatory conditions including osteoarthritis, cardiovascular disease and bone metastases. We have also demonstrated that a conjugated Sn-117m compound has been successfully delivered to the brain in humans. NeuroSn’s small targeting molecules linked to Sn-117m are under investigation in pre-clinical biodistribution and inflammatory cell binding studies.